Hunter syndrome, also known as Mucopolysaccharidosis type II (MPS II), is a rare X-linked lysosomal storage disease caused by deficiency of the enzyme iduronate-2-sulfatase (IDS)[1]. This enzyme is required for breaking down glycosaminoglycans (GAGs)—specifically heparan sulfate and dermatan sulfate. Without functional IDS, these GAGs accumulate in tissues throughout the body, leading to progressive multi-organ damage[1:1].
Unlike other MPS disorders, Hunter syndrome predominantly affects males, with an estimated incidence of 1 in 100,000-170,000 live births[2]. The disease presents with a spectrum of severity, from attenuated (slowly progressive) to severe (rapidly progressive) forms.
Hunter syndrome results from mutations in the IDS gene (Xq28), which encodes the enzyme iduronate-2-sulfatase[1:2]. The disease follows an X-linked recessive inheritance pattern:
Over 600 pathogenic variants of IDS have been identified, including:
Genotype-phenotype correlations exist: certain missense mutations are associated with the attenuated form, while nonsense mutations and large deletions typically cause severe disease[2:1].
Iduronate-2-sulfatase is a sulfatase enzyme that removes the sulfate group from the 2-position of iduronic acid residues in heparan sulfate and dermatan sulfate[1:3]. Without this enzymatic activity:
A critical feature of Hunter syndrome is the progressive neurocognitive decline seen in the severe form. GAG accumulation in neurons leads to[2:2]:
The blood-brain barrier (BBB) prevents conventional enzyme replacement therapies from reaching the CNS, making neurocognitive symptoms the most challenging aspect of treatment[4].
| System | Symptoms |
|---|---|
| Respiratory | Upper airway obstruction, sleep apnea, recurrent infections |
| Cardiovascular | Valve disease (mitral/aortic), cardiomyopathy, coronary artery disease |
| Skeletal | Dysostosis multiplex, short stature, joint stiffness, claw-hand deformities |
| Abdominal | Hepatomegaly, splenomegaly, inguinal/umbilical hernias |
| ENT | Chronic otitis media, hearing loss (conductive and sensorineural) |
| Ophthalmologic | Retinal degeneration, corneal clouding (less severe than MPS I) |
| Dermatologic | Characteristic "pebbly" papules on scapular region |
Patients with attenuated Hunter syndrome have a slower disease progression[2:4]:
Several countries have implemented newborn screening for MPS II:
Conventional ERT (prior to J-Brain Cargo):
Brain-Targeting ERT:
HSCT can provide some CNS benefit through microglial engraftment, but carries significant risks[2:5]:
An optimized version of JR-141 with enhanced BBB penetration efficiency[7:1]:
Experimental approaches targeting GAG synthesis[9]